Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Agios Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
AGIO
Nasdaq
2836
www.agios.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals (AGIO) Stock Looks Pricey Despite Its 39% Run
- Nov 7th, 2026 2:10 am
Agios Pharmaceuticals Inc (AGIO) (Q3 2026) Earnings Call Highlights: Revenue Surges 4x on ...
- Nov 6th, 2026 4:08 pm
Agios Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
- Nov 5th, 2026 3:05 pm
What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings Call
- Nov 5th, 2026 10:14 am
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates
- Nov 5th, 2026 5:15 am
Agios Pharmaceuticals: Q3 Earnings Snapshot
- Nov 5th, 2026 4:40 am
Agios Reports Third Quarter 2026 Financial Results and Provides Business Update
- Nov 5th, 2026 4:30 am
Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
- Nov 4th, 2026 7:01 am
Will FDA Review Delay Change Agios Stock Narrative
- Nov 4th, 2026 1:18 am
IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates
- Nov 3rd, 2026 4:25 am
Agios Sinks 18% as FDA Delays Sickle Cell Drug Decision to 2027 Despite Being “Launch-Ready”
- Oct 30th, 2026 9:56 am
Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA
- Oct 30th, 2026 5:00 am
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
- Oct 29th, 2026 7:00 am
LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Misses Revenue Estimates
- Oct 28th, 2026 2:45 pm
DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line
- Oct 21st, 2026 7:45 am
Did Priority Review Just Shift Agios Pharmaceuticals' (AGIO) Investment Narrative?
- Oct 20th, 2026 5:23 pm
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
- Oct 20th, 2026 6:59 am
FDA Decision Watch: What Investors Need To Know About Four Upcoming Drug Rulings
- Oct 19th, 2026 3:43 am
Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock?
- Oct 16th, 2026 6:41 am
4 High-Risk Stocks Built for Big Returns
- Oct 14th, 2026 4:28 am
Scroll